Amanda Mogoi, APRN
Nurse Practitioner · Wichita, KSNPI 1801332564
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Viiv Healthcare Company accounts for 73.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $4,475 and has fallen 80.5% since, to $872 in 2025. Among nurse practitioner clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $54.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$7K
- AbbVie$559
- Gilead$514
- Johnson & Johnson$216
- Merck$159
- Corium, LLC$141
- plus $706 from 12 others
What the payments were for
- Consulting fees$3,93045%
- Travel & lodging$3604%
- Food & beverage$4,51351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 67 | $6,508 |
| AbbVie | 27 | $559 |
| Gilead | 12 | $514 |
| Johnson & Johnson(2 entities) | 5 | $216 |
| Merck | 9 | $159 |
| Corium, LLC | 9 | $141 |
| Otsuka America Pharmaceutical, Inc. | 6 | $138 |
| Antares Pharma, Inc. | 6 | $122 |
| Astellas Pharma US Inc | 3 | $73 |
| Janssen Scientific Affairs, LLC | 1 | $54 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $53 |
| Lilly USA, LLC | 3 | $47 |
| Halozyme Inc | 3 | $47 |
| Novo Nordisk | 3 | $45 |
| AstraZeneca | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,803 in reported general payments places this provider in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,918 |
| Lansoprazole | 12 | $243 |
| Diclofenac Sodium | 13 | $165 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 13 | $62 |
| Topiramate | 11 | $32 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Wichita
- Constance JacobWichita$65K
- Catherine PowellWichita$50K
- Darine JamaleddineWichita$15K
- Krystal MitchellWichita$13K
- Jolene GrotheWichita$11K
- Christina StantonWichita$11K
- Sarah RookerWichita$10K
- Ayman HamadWichita$9K
- Jill AugustineWichita$8K
- Rebecca WernliWichita$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.